Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| VRXA | PRESS-RELEASE | neutral | 2/10 | VERAXA Biotech announced the expansion of its R&D facility in Heidelberg, Germany under a previously signed long-term le | Jun 24, 2026 |
| CALC | 8-K | bearish | 6/10 | CalciMedica amended its existing loan agreement with Avenue Venture Opportunities Fund II, extending the interest-only p | Jun 24, 2026 |
| ABSI | PRESS-RELEASE | bullish | 7/10 | Absci Corporation announced a $100 million underwritten offering of 13,495,277 shares at $7.41 per share, with participa | Jun 24, 2026 |
| ABSI | 8-K | bullish | 7/10 | Absci Corp announced positive interim Phase 1 data from the HEADLINE trial of ABS-201, a novel antibody targeting the pr | Jun 24, 2026 |
| ABSI | PRESS-RELEASE | bullish | 7/10 | Absci reported positive interim Phase 1 data for ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia | Jun 24, 2026 |
| LODE | PRESS-RELEASE | neutral | 3/10 | Comstock Inc. announced that its subsidiary Comstock Metals will open a solar panel recycling facility in Cambridge, Ohi | Jun 24, 2026 |
| TAK | 6-K | mixed | 6/10 | Takeda filed its 2026 Annual Integrated Report (FY2025, ended March 31, 2026) via Form 6-K. Core Revenue declined 2.6% a | Jun 24, 2026 |
| TAK | 6-K | neutral | 3/10 | Takeda announced the official appointment of Julie Kim as Representative Director, President & CEO, completing an 18-mon | Jun 24, 2026 |
| LKFT | 6-K | neutral | 3/10 | Lakefront Biotherapeutics disclosed the repurchase of 77,667 of its own ordinary shares between June 15-19, 2026, for a | Jun 24, 2026 |
| TAK | 6-K | neutral | 2/10 | Takeda filed a 6-K reporting resolutions from its 150th Annual General Meeting of Shareholders. Key outcomes include app | Jun 24, 2026 |
| NTHI | EFFECT | bearish | 5/10 | The SEC declared effective NeOnc Technologies' S-3 shelf registration (File No. 333-296788) on June 23, 2026. This allow | Jun 24, 2026 |
| AIM | EFFECT | bearish | 7/10 | AIM ImmunoTech's S-1 registration (File No. 333-296871) became effective on June 23, 2026, enabling the resale of up to | Jun 24, 2026 |
| NVO | 6-K | neutral | 3/10 | Novo Nordisk filed a routine 6-K disclosing weekly B-share repurchase transactions under its existing DKK 15 billion buy | Jun 24, 2026 |
| LODE | 8-K | bullish | 7/10 | Comstock Inc. has entered into a definitive agreement to sell 100% of its legacy mining assets (Comstock Mining LLC, Com | Jun 24, 2026 |
| LIMN | S-1 | neutral | 4/10 | Liminatus Pharma filed an S-1 registration statement for the resale of up to 20,688,000 shares of common stock by Armist | Jun 24, 2026 |
| MLTX | PRESS-RELEASE | bearish | 6/10 | MoonLake Immunotherapeutics priced a $200M underwritten public offering of 9M Class A ordinary shares at $20.00 per shar | Jun 23, 2026 |
| SYRE | CLUSTER | bearish | 7/10 | Two directors at Spyre Therapeutics executed massive open-market sales totaling $401.66M in a 7-day window, with the lar | Jun 23, 2026 |
| QURE | PRESS-RELEASE | bearish | 6/10 | uniQure priced an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, expecting approximately | Jun 23, 2026 |
| VSTM | 8-K | bullish | 6/10 | Verastem announced positive preliminary Phase 1/2 data for its KRAS G12D (ON/OFF) inhibitor VS-7375 across pancreatic, c | Jun 23, 2026 |
| DYN | 3 | neutral | 2/10 | Barry Greene filed an initial beneficial ownership statement (Form 3) with the SEC, indicating he has become an officer, | Jun 23, 2026 |
| INMB | 8-K | bullish | 7/10 | Inmune Bio announced receipt of written alignment from the UK MHRA following a May 12, 2026 pre-MAA Scientific Advice me | Jun 23, 2026 |
| QDEL | 8-K | neutral | 3/10 | QuidelOrtho appointed Micah Young as CFO effective July 6, 2026, succeeding retiring CFO Joseph Busky. Young previously | Jun 23, 2026 |
| IDYA | 8-K | neutral | 2/10 | IDEAYA Biosciences filed an 8-K reporting results from its 2026 Annual Meeting of Stockholders, where all three proposal | Jun 23, 2026 |
| ORGN | 25-NSE | bearish | 8/10 | Nasdaq filed a Form 25-NSE to delist and deregister Origin Materials' warrants under Rule 12d2-2(a)(2), effective immedi | Jun 23, 2026 |
| JANX | 8-K | neutral | 2/10 | Janux Therapeutics disclosed the departure of Chief Medical Officer William Go, M.D., Ph.D. on June 23, 2026, under circ | Jun 23, 2026 |
| ANIK | 8-K | neutral | 4/10 | Anika Therapeutics held its 2026 Annual Meeting on June 18, 2026. Stockholders approved an amendment to the 2017 Omnibus | Jun 23, 2026 |
| SDGR | 8-K | neutral | 2/10 | Schrodinger held its 2026 Annual Meeting on June 22, where stockholders approved a 3,000,000-share increase to the 2022 | Jun 23, 2026 |
| PCVX | 8-K | neutral | 2/10 | Vaxcyte announced the retirement of board member Jacks Lee and the appointment of Moncef Slaoui as an independent Class | Jun 23, 2026 |
| ONC | 144 | neutral | 3/10 | Director John Oyler filed a Form 144 notice of intent to sell 3,410 ADSs (~$933,592 at the filing date) of BeOne Medicin | Jun 23, 2026 |
| QNRX | 8-K | neutral | 4/10 | Quoin Pharmaceuticals announced FDA conditional approval of QYLEKI as the proposed brand name for QRX003, its investigat | Jun 23, 2026 |